Severe cognitive decline in long-term care is related to gut microbiome production of metabolites involved in neurotransmission, immunomodulation, and autophagy - Shoubridge, Andrew P.; Carpenter, Lucy; Flynn, Erin; Papanicolas, Lito E.; Collins, Josephine; Gordon, David; Lynn, David J.; Whitehead, Craig; Leong, Lex E.X.; Cations, Monica; De Souza, David P.; Narayana, Vinod K.; et al. (medRxiv, 2024)
Ageing-associated cognitive decline affects more than half of those in long-term residential aged care. Emerging evidence suggests that gut microbiome-host interactions influence the effects of modifiable risk factors. We investigated the relationship between gut microbiome characteristics and severity of cognitive impairment (CI) in 159 residents of long-term aged care. Severe CI was associated with a significantly increased abundance of proinflammatory bacterial species, including Methanobrevibacter smithii and Alistipes finegoldii, and decreased relative abundance of beneficial bacterial clades. Severe CI was associated with increased microbial capacity for methanogenesis, and reduced capacity for synthesis of short-chain fatty acids, neurotransmitters glutamate and gamma-aminobutyric acid, and amino acids required for neuro-protective lysosomal activity. These relationships were independent of age, sex, antibiotic exposure, and diet. Our findings implicate multiple gut microbiome-brain pathways in ageing-associated cognitive decline, including inflammation, neurotransmission, and autophagy, and highlight the potential to predict and prevent cognitive decline through microbiome-targeted strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by an Australian Medical Research Future Fund (MRFF) grant from the Australian Department of Health (GNT1152268). The Australian Department of Health reviewed the study proposal, but did not play a role in study design, data collection, analysis, interpretation, or manuscript writing. GBR is supported by a National Health and Medical Research Council (NHMRC) Senior Research Fellowship (GNT119378) and a Matthew Flinders Professorial Fellowship. MCI is supported by The Hospital Research Foundation Mid-Career Fellowship (MCF-27-2019) and NHMRC Investigator Grant (GNT119378). DJL is supported by an EMBL Australia Group Leader Award. SLT is supported by an NHMRC Emerging Leadership grant (GNT2008625).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study was obtained from the Southern Adelaide Clinical Human Research Ethics Committee (HREC/18/SAC/244). Participants provided written informed consent themselves or where third-party consent was required, a legal guardian or family member with power of attorney provided consent on their behalf.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes